Introduction and Objective: Time to treatment target is a consideration in clinical decision making. Additionally, greater magnitudes of sustained body weight (BW) reduction are shown to provide added health benefits. In SURMOUNT-5, once weekly tirzepatide (TZP) at the maximum tolerated dose (MTD) (10/15mg) resulted in significantly greater BW reduction vs semaglutide (SEMA) MTD (1.7/2.4mg) in adults living with obesity. This post hoc analysis assessed time to reach BW reduction thresholds and continuous time spent in BW control with TZP vs SEMA in SURMOUNT-5.Methods: Participants randomized (1:1) to receive TZP MTD (N=374) or SEMA MTD (N=376) and with an on-treatment BW measurement at week 72 were included in analysis. Among participants achieving BW reduction thresholds (≥5%, ≥10%, ≥15%, ≥20%, ≥25%, ≥30%) at week 72, time to first reaching thresholds and continuous time spent at each threshold was descriptively analyzed. Sustained BW reduction was defined as achieving BW reduction threshold at a postbaseline visit and at all subsequent visits (±3%) up to week 72.Results: At week 72, time to reach thresholds was shorter with TZP vs SEMA except ≥25%, which was similar (median weeks: 8 vs 12 for ≥5%, 16 vs 20 for ≥10%, 24 vs 36 for ≥15%, 36 vs 48 for ≥20%, 48 vs 48 for ≥25%, and 48 vs 52 for ≥30%). Of the participants who achieved and sustained the defined thresholds during the 72-week trial, median duration in weeks of sustained BW reduction was longer with TZP vs SEMA: 64 vs 60 for ≥5%, 56 vs 52 for ≥10%, 48 vs 36 for ≥15%, 36 vs 25 for ≥20%, 25 vs 24 for ≥25%, and 24 vs 21 for ≥30%.Conclusion: In this post hoc analysis, participants in the TZP arm reached clinically meaningful BW reduction sooner vs SEMA in adults living with obesity. For participants who achieved BW reduction thresholds during the 72-week trial, both treatment groups had sustained BW reduction. Additional studies are needed to further assess sustainability of BW reduction and its clinical impact.
D.B. Horn: Consultant; Eli Lilly and Company. Speaker’s Bureau; Eli Lilly and Company. Research Support; Eli Lilly and Company. Consultant; Amgen Inc. Advisory Panel; Novo Nordisk. Consultant; Novo Nordisk. Speaker’s Bureau; Novo Nordisk. Research Support; Novo Nordisk. L.J. Aronne: Consultant; Novo Nordisk. Research Support; Novo Nordisk. Consultant; Lilly USA LLC. Research Support; Lilly USA LLC. J.P. Dunn: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. H.T. Hoffmann: Employee; Eli Lilly and Company. B.L. Falcon: Employee; Eli Lilly and Company. D. Cao: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. C. Lee: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company.
Eli Lilly and Company
Source link
Leave a Reply